Clinical Trials Logo

Bladder Tumors clinical trials

View clinical trials related to Bladder Tumors.

Filter by:
  • None
  • Page 1

NCT ID: NCT05699135 Terminated - Bladder Cancer Clinical Trials

A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer

Start date: March 9, 2023
Phase:
Study type: Observational

The purpose of this study is to learn about the safety and effects of the study medicine (called avelumab) for the treatment of advanced bladder cancer. This study is including participants who: - Participated in the Canadian avelumab patient support program - Have been diagnosed with advanced bladder cancer - Have been treated with platinum-based chemotherapy without their disease progressing All participants in this study have previously received avelumab first-line maintenance for the treatment of their advanced bladder cancer. Pfizer will examine the experiences of people receiving the study medicine. This will help determine the efficacy and safety of the study medicine for the treatment of bladder cancer.

NCT ID: NCT05072600 Recruiting - Bladder Cancer Clinical Trials

Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

Start date: December 7, 2021
Phase: Phase 2
Study type: Interventional

This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment (TMT) and achieved CR. All participants will receive pembrolizumab monotherapy per 21 days no longer than 17 cycles until disease progression or death.

NCT ID: NCT03335059 Terminated - Bladder Cancer Clinical Trials

Mitomycin C Intravesical Chemotherapy in Conjunction With Synergo® Radiofrequency-Induced Hyperthermia for Treatment of Carcinoma in Situ Non-Muscle Invasive Bladder Cancer Patients Unresponsive to Bacillus Calmette-Guérin, With or Without Papillary Tumors.

RITE-USA
Start date: April 4, 2019
Phase: Phase 3
Study type: Interventional

This study will determine whether Synergo® RITE + MMC treatment is efficacious as second-line therapy for CIS NMIBC BCG-unresponsive patients with or without papillary NMIBC, through examination of the complete response rate (CRR) and disease-free duration for complete responders. The study will also explore progression-free survival time, bladder preservation rate, and overall survival time. The study will address an unmet need to identify a treatment effective in both ablating the disease and providing a prolonged disease-free period for patients. Ideally, the treatment will delay progression to invasive disease, thus preserving the bladder.

NCT ID: NCT02897765 Completed - Lung Cancer Clinical Trials

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

Start date: October 2016
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer. The study also will investigate if NEO-PV-01 + adjuvant with nivolumab may represent a substantial improvement over other available therapies such as nivolumab alone. All eligible patients will receive NEO-PV-01 + adjuvant and nivolumab while on this trial.

NCT ID: NCT02659332 Enrolling by invitation - Bladder Tumors Clinical Trials

Laser Treatment of Bladder Tumors in the Outpatient Department

Start date: February 2015
Phase: N/A
Study type: Interventional

- Primary Objective: To show that small pTa bladder tumors can be removed with diode laser in an outpatient department. - Secondary Objective: To evaluate the patients' symptoms during and after the laser TURBT. - Tertiary Objective: To evaluate the rate of remnant tumor tissue one month after the laser TURBT.

NCT ID: NCT02496442 Not yet recruiting - Clinical trials for Prostatic Hyperplasia

Aqueduct Irrigation System Clinical Protocol: Medical Device Investigational Plan

Start date: July 2015
Phase: N/A
Study type: Interventional

A. Synopsis 1. This protocol comes to direct the experiment to be performed on the Aqueduct Automatic Continuous Irrigation system. 2. The Aquaduct System is aimed at reducing risks to the patient by decreasing the irrigation fluid pressure he may be exposed to, reducing the procedure time and therefore the anesthesia time, reducing the manual handling of the sterile bags and the risk of contamination and more. 3. In general since there is no new procedure suggested and the equipment does not actually come into contact with the human body in any direct way, there is no need to have a clinical study for the regulation purpose. The reason for performing this experiment is to demonstrate the new system and to find out the best way to operate it in order to improve the process and reduce risks. 4. This information will serve the development of most suitable automation solution for achieving the long desired continuous irrigation. 5. The experiment will be performed in the OR in MIS procedures, and will replace the standard gravitational manual method of performing the irrigation. The surgeons and the medical staff of the OR will be directed with the set up and operation of the system prior to using it. The experiment will be accompanied at all times with a knowledgeable representative of the research originator. 6. A maximum of 30 procedures will be analyzed during a period of approximately one month. The surgeons and the medical staff will report their impression of using the system during the procedures and will recommend the best settings achieved. This information will be used to improve the system performance and design.

NCT ID: NCT00462488 Completed - Bladder Cancer Clinical Trials

Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and tolerability of Vicinium when administered as a monotherapy intravesical instillation in patients with non-invasive urothelial carcinoma in situ (CIS) who failed previous treatment with Bacille Calmette Guérin (BCG).